Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NRX1
UPID:
PNO1_HUMAN
Alternative names:
Partner of NOB1
Alternative UPACC:
Q9NRX1; A8K6Q0; Q53G13; Q8WVB8
Background:
RNA-binding protein PNO1, also known as Partner of NOB1, plays a crucial role in the small subunit (SSU) processome, essential for the early stages of ribosomal biogenesis. It facilitates RNA folding, modifications, and cleavage, contributing to the efficient assembly of ribosomal subunits. PNO1's activity is pivotal in enhancing the dimethylation of adenosines in 18S rRNA, a modification critical for ribosome function.
Therapeutic significance:
Understanding the role of RNA-binding protein PNO1 could open doors to potential therapeutic strategies. Its involvement in ribosome biogenesis and RNA processing highlights its importance in cellular function and presents a novel target for drug discovery efforts aimed at diseases where protein synthesis is disrupted.